Header Logo

Connection

Frederick Raal to Adolescent

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Adolescent.
Frederick Raal
Connection Strength
2,140
Adolescent
  1. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
    View in: PubMed
    Score: 0,143
  2. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
    View in: PubMed
    Score: 0,138
  3. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
    View in: PubMed
    Score: 0,135
  4. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021 Nov-Dec; 15(6):814-821.
    View in: PubMed
    Score: 0,114
  5. Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
    View in: PubMed
    Score: 0,106
  6. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
    View in: PubMed
    Score: 0,105
  7. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
    View in: PubMed
    Score: 0,095
  8. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018 04 07; 39(14):1162-1168.
    View in: PubMed
    Score: 0,089
  9. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):860-869.
    View in: PubMed
    Score: 0,078
  10. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
    View in: PubMed
    Score: 0,077
  11. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
    View in: PubMed
    Score: 0,070
  12. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
    View in: PubMed
    Score: 0,070
  13. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
    View in: PubMed
    Score: 0,065
  14. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab Syndr Relat Disord. 2012 Oct; 10(5):351-7.
    View in: PubMed
    Score: 0,060
  15. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
    View in: PubMed
    Score: 0,058
  16. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011 Nov 15; 124(20):2202-7.
    View in: PubMed
    Score: 0,057
  17. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry. Eur Heart J. 2025 Mar 24; 46(12):1127-1140.
    View in: PubMed
    Score: 0,036
  18. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
    View in: PubMed
    Score: 0,034
  19. Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia. JAMA Cardiol. 2024 Apr 01; 9(4):313-322.
    View in: PubMed
    Score: 0,034
  20. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis. 2003 Dec; 171(2):273-9.
    View in: PubMed
    Score: 0,033
  21. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022 02 19; 399(10326):719-728.
    View in: PubMed
    Score: 0,029
  22. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Jun; 150(2):421-8.
    View in: PubMed
    Score: 0,026
  23. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999 Dec 01; 84(11):1344-6, A7.
    View in: PubMed
    Score: 0,025
  24. Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
    View in: PubMed
    Score: 0,025
  25. Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. J Intern Med. 1999 Jul; 246(1):75-80.
    View in: PubMed
    Score: 0,024
  26. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 03 15; 19(1):61.
    View in: PubMed
    Score: 0,024
  27. Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Clin Genet. 1998 Jul; 54(1):74-8.
    View in: PubMed
    Score: 0,023
  28. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. J Clin Lipidol. 2018 Sep - Oct; 12(5):1199-1207.
    View in: PubMed
    Score: 0,023
  29. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
    View in: PubMed
    Score: 0,022
  30. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997 Dec; 135(2):249-56.
    View in: PubMed
    Score: 0,022
  31. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
    View in: PubMed
    Score: 0,022
  32. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29; 70(9):1162-1170.
    View in: PubMed
    Score: 0,021
  33. A double mutant LDL receptor allele in a cypriot family with heterozygous familial hypercholesterolemia. Hum Genet. 1997 Jul; 100(1):101-3.
    View in: PubMed
    Score: 0,021
  34. CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet. 1997 Jun; 51(6):394-8.
    View in: PubMed
    Score: 0,021
  35. Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease. Clin Chim Acta. 1997 Feb 03; 258(1):31-46.
    View in: PubMed
    Score: 0,021
  36. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
    View in: PubMed
    Score: 0,019
  37. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21; 36(36):2425-37.
    View in: PubMed
    Score: 0,018
  38. Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. Atherosclerosis. 1995 May; 115(1):9-15.
    View in: PubMed
    Score: 0,018
  39. Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. Atherosclerosis. 1994 Jun; 107(2):213-9.
    View in: PubMed
    Score: 0,017
  40. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015 Jul; 22(7):849-54.
    View in: PubMed
    Score: 0,017
  41. The age of onset and sex distribution of insulin-dependent diabetes mellitus in Africans in South Africa. Postgrad Med J. 1993 Jul; 69(813):552-6.
    View in: PubMed
    Score: 0,016
  42. Fat, protein and carbohydrate content of diets of white insulin-dependent diabetic adolescents and young adults. S Afr Med J. 1992 Apr 18; 81(8):399-402.
    View in: PubMed
    Score: 0,015
  43. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010 Feb; 156(2):231-6.e1-3.
    View in: PubMed
    Score: 0,012
  44. Haematological abnormalities in the acquired immunodeficiency syndrome. S Afr Med J. 1988 Aug 20; 74(4):157-60.
    View in: PubMed
    Score: 0,011
  45. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar; 197(1):400-6.
    View in: PubMed
    Score: 0,011
  46. Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. Am J Hum Genet. 2001 May; 68(5):1172-88.
    View in: PubMed
    Score: 0,007
  47. Circulating endothelium-related adhesion molecules in black South African patients with Graves' disease. Endocrine. 2000 Feb; 12(1):21-3.
    View in: PubMed
    Score: 0,006
  48. Insulin receptor substrate-1 gene variants in lipoatrophic diabetes mellitus and non-insulin-dependent diabetes mellitus: a study of South African black and white subjects. Hum Genet. 1997 Nov; 101(1):118-9.
    View in: PubMed
    Score: 0,005
  49. Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? Clin Endocrinol (Oxf). 1997 Mar; 46(3):365-8.
    View in: PubMed
    Score: 0,005
  50. Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 1995 Mar; 113(2):289-92.
    View in: PubMed
    Score: 0,005
  51. Selected risk factors for coronary heart disease in male scholars from the major South African population groups. S Afr Med J. 1993 Dec; 83(12):891-7.
    View in: PubMed
    Score: 0,004
  52. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb. 1993 Jul; 13(7):1076-81.
    View in: PubMed
    Score: 0,004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.